NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis $2.03 -0.10 (-4.69%) As of 10/30/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC Filings About AlloVir Stock (NASDAQ:ALVR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AlloVir alerts:Sign Up Key Stats Today's Range$1.97▼$2.0850-Day Range$1.80▼$4.2052-Week Range$7.96▼$24.15Volume60,195 shsAverage Volume15,685 shsMarket Capitalization$10.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AlloVir, Inc. was a clinical-stage biotechnology company focused on developing allogeneic, or donor-derived, virus-specific T-cell therapies for people whose immune systems are weakened by conditions such as cancer, organ transplantation, or hematopoietic stem-cell transplantation. The company operated under the name ViraCyte before adopting the AlloVir name. Its lead investigational product, posoleucel, was designed to target multiple viruses that can cause serious disease in immunocompromised patients, including adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6. AlloVir also developed additional T-cell therapy candidates aimed at respiratory viruses and SARS-CoV-2. These products were investigational and were not approved for general commercial use. AlloVir conducted clinical development activities primarily in the United States and through international research collaborations. In 2023, the company announced plans to discontinue its clinical programs and wind down operations after reporting unfavorable results from a pivotal study of posoleucel. As a result, AlloVir is principally described as a former biotechnology company rather than an active commercial-stage business.AI Generated. May Contain Errors. Read More Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVR Stock News HeadlinesKLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) StockholdersAugust 3, 2026 | globenewswire.comALLOVIR INVESTIGATION: Bragar Eagel & Squire, P.C. Continues Investigation into AlloVir, Inc. on Behalf of Long-Term StockholdersOctober 16, 2025 | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 3 at 1:00 AM | Behind the Markets (Ad)ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. ...August 6, 2025 | gurufocus.comALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 6, 2025 | globenewswire.comKalaris Announces Closing of Merger with AlloVirMarch 18, 2025 | globenewswire.comAlloVir shareholders approve merger with Kalaris TherapeuticsMarch 14, 2025 | investing.comAlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of MergerMarch 13, 2025 | finanznachrichten.deSee More Headlines ALVR Stock Analysis - Frequently Asked Questions How have ALVR shares performed this year? AlloVir's stock was trading at $8.44 at the beginning of the year. Since then, ALVR stock has decreased by 75.9% and is now trading at $2.03. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.15) EPS for the quarter, topping analysts' consensus estimates of ($2.30) by $1.15. When did AlloVir's stock split? AlloVir shares reverse split on the morning of Thursday, January 16th 2025.The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did AlloVir IPO? AlloVir (ALVR) raised $276 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 16,250,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Pfizer (PFE), Pacific Biosciences of California (PACB), Palantir Technologies (PLTR), Tesla (TSLA), Advanced Micro Devices (AMD), Lucid Group (LCID) and Skillz (FIRY). Company Calendar Last Earnings8/14/2024Today11/03/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALVR CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees110Year Founded2013Profitability EPS (Trailing Twelve Months)($20.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.03% Return on Assets-61.27% Debt Debt-to-Equity RatioN/A Current Ratio86.78 Quick Ratio86.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$29.35 per share Price / Book0.07Miscellaneous Outstanding Shares5,043,000Free Float3,425,000Market Cap$10.24 million OptionableNo Data Beta0.63 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ALVR) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
